Non-exclusive rebate agreement for Golimumab
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...
The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Golimumab (ATC L04AB06).
- Open-House participation model: all interested pharmaceutical companies may join if they meet and accept the participation conditions.
Show full summary
This is an Open-House framework-style supply arrangement for non-exclusive pharmaceutical rebate agreements for Golimumab (ATC L04AB06) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the stated conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract period runs until 31.12.2026 at the latest. Submission is electronic via DTVP communication, but not via the bidder tool; the first participation deadline was updated to 03.12.2025. Procurement documents are referenced but their extracted text is not provided, so key document-based details remain unverified.
Risks
The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...
The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.
Eligibility
- The bidder must submit the completed 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' to evidence absence of mandatory/optional exclusion grounds under §§ 123, 124 GWB.
Administrative
- The bidder must submit the 'Eigenerklärung Russlandsanktionen' confirming no Russia-related link within the meaning of Article 5k of Regulation (EU) 833/2014 as amended.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Golimumab
Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for medicines containing the active substance Golimumab. The arrangement is described as an Open-House model, with no exclusivity and no individual negotiations. Performance/place of performance is stated as Dresden, Germany, but this is the notice geography and not necessarily the delivery model details.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 20 Oct 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 692978-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice refers to key documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') but...
The notice states that participation documents must be submitted via the DTVP communication function and not via the bi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications